Temporal trend in the level of 90K glycoprotein after HIV seroconversion among persons coinfected with hepatitis C virus

Infection

Volumn 33, Issue 2, 2005, Pages 101-102

  Dorrucci, M ^a   Ciccozzi, M ^a   Iacobelli, S ^b   Rezza, G ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; GLYCOPROTEIN 90K; LAMIVUDINE; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BLOOD LEVEL; CASE REPORT; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER CIRRHOSIS; MALE; PROGNOSIS; SEROCONVERSION; SEROLOGY; SUPERINFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; DISEASE PROGRESSION; FEMALE; GLYCOPROTEINS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 17844382699     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-4076-6     Document Type: Letter

References (12)

1. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A: Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993; 268: 14245-14249.
2. D'Ostilio N, Sabatino G, Natoli C, Ullrich A, Iacobelli S: 90K (Mac-2 BP) in human milk. Clin Exp Immunol 1996; 104: 543-546.
3. Linsley PS, Horn D, Marquardt H, Brown JP: Identification of a novel serum protein secreted by lung carcinoma cells. Biochemistry 1986; 25: 2978-2986.
4. Jallal B, Powell J, Zachwieja J, Brakebusch C: Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res 1995; 55: 3223-3227.
5. Iacobelli S, Bucci I, D'Egidio M: Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett 1993 15; 319: 59-65.
6. Iacobelli S, Ullrich A, Tinari N, Ortona L, Tamburrini E, D'Egidio M, Ghinelli F, Sighinolfi L, Piazza M, Chirianni A, Guerra L, Natoli C: The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 450-456.
7. Laferte S, Loh LC, Keeler V: Monoclonal antibodies specific for human tumor-associated antigen 90K/Mac-2 binding protein: tools to examine protein conformation and function. J Cell Biochem 2000; 77: 540-559.
8. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S: Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 212-217.
9. Rezza G, Dorrucci M, Pezzotti P: The seroconversion study on the natural history of HIV infection. In: Nicolosi A (ed): HIV epidemiology: models and methods. Raven Press, New York 1994, pp 279-289.
10. Brown H, Prescott R: Applied mixed models in medicine. John Wiley & Sons, New York 1999.
11. Kittl EM, Hofmann J, Hartmann G, Sebesta C, Beer F, Bauer K, Huber KR: Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin. Chem Lab Med 2000; 38: 205-208.
12. Correale M, Giannuzzi V, Iacovazzi PA, Valenza MA, Lanzillotta S, Abate I, Quaranta M, Caruso ML, Elba S, Manghisi OG: Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis. Anticancer Res 1999; 19: 3469-3472.